Cheap, portable and easy-to-use tests developed by a Turkish scientist in his laboratories at the Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology will be put into markets in coming years.
Assistant Professor Utkan Demirci of Medicine and Health Sciences and Technology developed a number of micro-devices including a microchip which diagnoses HIV/AIDS within a few minutes.
34-year-old scientist and his 40-member team at the Harvard Medical SchoolBrigham & Women's Hospital apply nano and microscale technologies to manipulate cells in nanoliter volumes to enable solutions to real world problems in medicine including applications in infectious disease diagnostics and monitoring, cell encapsulation and assembly for cryobiology, and tissue engineering.
Demirci further developed the microchip he invented in 2006 to diagnose AIDS, and tested it on 115 patience in Tanzania last year. Results of the tests were published.
Another microchip developed by Demirci and his team enables patients to determine their sperm count and quality in only 30 minutes.
Demirci's scientific work has been recognized by numerous national and international awards. Demirci was given the Chinese International Young Scientist Award by the National Science Foundation of China in 2010. Demirci was recognized by Junior Chamber International (JCI) globally among the ten outstanding young persons of the world in "Medical Innovation" in 2009. In 2008, Demirci was given the Department of Medicine, Harvard Medical School-Young Investigator Award.
Demirci received the Coulter Foundation Early Career Award in Biotechnology in 2007 and in 2009. He was also awarded by Nano-Biotechnology Award by the National Science Council of Turkey and The Turkish Industrialists' and Businessmen's Association (TUSIAD).
In 2006, he was selected to TR-35 as one of the world's top 35 young innovators under the age of 35 by the MIT Technology Review. He is one of the few recipients of the prestigious Full Presidential Fellowship given by the Turkish Ministry of Education. In 2004, he lead a team that won the Stanford University Entrepreneur's Challenge Competition and Global Start-up Competition in Singapore based on his doctoral work.
A new cancer drug will be tested as part of a joint effort by AstraZeneca and Lilly.
Smart technology and regulation will aid challenges in global power sector, helping to lower the carbon emitted globally.
A deal between the richest nations in the world has been seen as unlikely, as OECD seeks to phase out export credits.
Soon more than 1 billion consumers in developing nations will be able to buy their first air conditioner, increasing energy demand which will impact global warming
The European Union has given new authorization for 10 new types of genetically modified crops have been approved for a 10 year use for human consumption and animal feed.
Guinea's President Alpha Conde announced new emergency measures in Ebola fight on Saturday
'Meetings happened. Action didn’t,' says Medecins Sans Frontieres report.
WHO said that on many levels, the world is better prepared now than ever before for aflu pandemic
Myanmar health officals say an outbreak of H5N1 bird flu in Mandalay
Tokyo Electric said it has been aware since last spring that radiation levels in water running in one of the plant gutters rise when it rains
Safe drinking water is available at about one-third of the level it was before the conflict erupted nearly five years ago, and supplies are cut-off to punish civilians at times
Elephants in Angola, which suffered decades of civil war, have been observed avoiding heavily-mined areas, suggesting their trunks were warning them to stay away.
Favipiravir halved death rate among some to 15 pct, but WHO says more research required on drug
The first medicine containing stem cells to treat a rare condition caused by burns to the eye has approved.
940 parasite samplescollected at 55 malaria treatment centres across Myanmar and its border regions. They found that almost 40 percent of the samples had mutations in their so-called kelch gene, K13 -- a known genetic signal of artemisinin drug resistance.
Yaws is known to be prevalent in 12 countries in areas where people have little access to healthcare, mainly in West and Central Africa, Asia and the Pacific Islands.